ZA201703305B - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix depositionInfo
- Publication number
- ZA201703305B ZA201703305B ZA2017/03305A ZA201703305A ZA201703305B ZA 201703305 B ZA201703305 B ZA 201703305B ZA 2017/03305 A ZA2017/03305 A ZA 2017/03305A ZA 201703305 A ZA201703305 A ZA 201703305A ZA 201703305 B ZA201703305 B ZA 201703305B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- preventing
- conditions
- methods
- extracellular matrix
- Prior art date
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title 1
- 230000001594 aberrant effect Effects 0.000 title 1
- 230000008021 deposition Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000002744 extracellular matrix Anatomy 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080784P | 2014-11-17 | 2014-11-17 | |
| US14/943,752 US10500249B2 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/061118 WO2016081475A1 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201703305B true ZA201703305B (en) | 2020-05-27 |
Family
ID=55960752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/03305A ZA201703305B (en) | 2014-11-17 | 2017-05-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10500249B2 (enExample) |
| EP (1) | EP3220943A4 (enExample) |
| JP (1) | JP2018501201A (enExample) |
| KR (1) | KR20170083063A (enExample) |
| CN (1) | CN107106650A (enExample) |
| AU (1) | AU2015350151A1 (enExample) |
| BR (1) | BR112017010238A2 (enExample) |
| CA (1) | CA2967621A1 (enExample) |
| MX (1) | MX2017006372A (enExample) |
| RU (1) | RU2017121090A (enExample) |
| SG (1) | SG11201703939XA (enExample) |
| WO (1) | WO2016081475A1 (enExample) |
| ZA (1) | ZA201703305B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001379WA (en) * | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| WO2019070908A1 (en) * | 2017-10-03 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CN110575540B (zh) * | 2018-06-07 | 2021-11-02 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
| CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
| CN113952821A (zh) * | 2021-07-22 | 2022-01-21 | 上海安居乐环保科技股份有限公司 | 一种罐区装卸区废气综合治理方法及系统 |
| CN113730551B (zh) * | 2021-09-02 | 2022-11-25 | 徐州医科大学 | Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用 |
| CN118388635B (zh) * | 2024-06-24 | 2024-10-11 | 山东美瑞生物技术有限公司 | 一种提高皮肤修复功能的重组人源化胶原蛋白的制备方法 |
| CN118571492B (zh) * | 2024-08-02 | 2024-10-18 | 天津市胸科医院 | 基于组织边界影响的主动脉夹层患者并发症风险预测模型 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AT396872B (de) | 1985-07-30 | 1993-12-27 | Glaxo Group Ltd | Gerät zur verabreichung von medikamenten in pulverform |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| KR100386337B1 (ko) | 1993-12-09 | 2004-03-24 | 토마스 제퍼슨 대학교 | 진핵세포에서부위-특이적돌연변이를위한화합물과그방법 |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| DK1808438T3 (da) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| EP2617431B1 (en) * | 2007-01-10 | 2017-04-12 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| NL1033850C2 (nl) | 2007-05-15 | 2008-11-18 | 3Force B V | Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen. |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| DK2349310T3 (da) * | 2008-10-20 | 2014-08-11 | Moerae Matrix Inc | Polypeptid til behandling eller forebyggelse af adhæsioner |
| BRPI0922448A2 (pt) * | 2008-12-10 | 2021-02-17 | Purdue Research Foundation | inibidor com base em peptídeo penetrante celular de quinases |
| US20110288036A1 (en) * | 2010-05-24 | 2011-11-24 | Cynthia Lander | Methods for Treating or Preventing Vascular Graft Failure |
| ES2711670T3 (es) | 2011-04-12 | 2019-05-06 | Moerae Matrix Inc | Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar |
| US9452218B2 (en) * | 2012-03-09 | 2016-09-27 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| US9750718B2 (en) * | 2012-12-12 | 2017-09-05 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity |
-
2015
- 2015-11-17 BR BR112017010238-2A patent/BR112017010238A2/pt not_active Application Discontinuation
- 2015-11-17 RU RU2017121090A patent/RU2017121090A/ru not_active Application Discontinuation
- 2015-11-17 AU AU2015350151A patent/AU2015350151A1/en not_active Abandoned
- 2015-11-17 SG SG11201703939XA patent/SG11201703939XA/en unknown
- 2015-11-17 US US14/943,752 patent/US10500249B2/en not_active Expired - Fee Related
- 2015-11-17 CA CA2967621A patent/CA2967621A1/en not_active Abandoned
- 2015-11-17 KR KR1020177014506A patent/KR20170083063A/ko not_active Withdrawn
- 2015-11-17 JP JP2017526674A patent/JP2018501201A/ja active Pending
- 2015-11-17 EP EP15861651.6A patent/EP3220943A4/en not_active Withdrawn
- 2015-11-17 CN CN201580062363.0A patent/CN107106650A/zh active Pending
- 2015-11-17 MX MX2017006372A patent/MX2017006372A/es unknown
- 2015-11-17 WO PCT/US2015/061118 patent/WO2016081475A1/en not_active Ceased
-
2017
- 2017-05-12 ZA ZA2017/03305A patent/ZA201703305B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3220943A4 (en) | 2018-08-01 |
| US10500249B2 (en) | 2019-12-10 |
| MX2017006372A (es) | 2017-08-21 |
| RU2017121090A3 (enExample) | 2019-06-10 |
| CA2967621A1 (en) | 2016-05-26 |
| EP3220943A1 (en) | 2017-09-27 |
| CN107106650A (zh) | 2017-08-29 |
| WO2016081475A1 (en) | 2016-05-26 |
| RU2017121090A (ru) | 2018-12-20 |
| JP2018501201A (ja) | 2018-01-18 |
| SG11201703939XA (en) | 2017-06-29 |
| KR20170083063A (ko) | 2017-07-17 |
| US20160136234A1 (en) | 2016-05-19 |
| BR112017010238A2 (pt) | 2018-02-06 |
| AU2015350151A1 (en) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201703305B (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| SG10201604560TA (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| PT3261640T (pt) | Agonistas de 5ht para tratamento de distúrbios de epilepsia | |
| GB201412201D0 (en) | Two-step deposition process | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| IL250715A0 (en) | Preparations and methods for the treatment of cultural disorders | |
| LT3164394T (lt) | Gls1 inhibitoriai, skirti ligų gydymui | |
| EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
| IL259486A (en) | Substances for the treatment of diseases associated with unwanted cell proliferation | |
| ZA201705148B (en) | Pharmaceutical composition for treating cancer, containing lactate metal salt | |
| EP3269084A4 (en) | Subscriber identity pattern | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| SG11201701135WA (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| IL252197A0 (en) | A method for treating, preventing or reducing the risk of skin infection | |
| ZA201608820B (en) | Method for treating drug resistant cancer | |
| PT3565592T (pt) | Tratamento de doenças metabólicas através da inibição da ativação da miostatina | |
| PL3347323T3 (pl) | Proces osadzania | |
| SG11201704701YA (en) | Pharmacotherapy for preventing or treating glaucoma | |
| EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| HK1236829A1 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| HK1240089A1 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| EP3210602A4 (en) | Composition for preventing or treating neurodegenerative diseases, containing ramalin | |
| HK1194983A (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| EP3354271A4 (en) | Agent for treating arthrological diseases |